IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
Relative valuation derived from Healthcare sector median benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Multiples adjusted for extreme outliers and non-recurring volatility.
Auditing capital efficiency...
Quality Profile Audit
Score: 50GRADE C+
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation.
Return on Equity
Profit generated per dollar of shareholder equity
9.4%
Sector: -43.5%
Dividend Analysis audit
No Dividend
This company does not currently pay a dividend.
Analyst Projections
Analyst Consensus
Unlock Valuation Tools
Sign up for free access to institutional-quality research tools.
Based on our 6-factor quantitative model, VIEMED HEALTHCARE, INC. (VMD) receives a "Hold" rating with a composite score of 53.4/100, ranked #167 out of 4446 stocks. Key factor scores: Quality 50/100, Value 63/100, Momentum 60/100. This is quantitative analysis only — not investment advice.
VIEMED HEALTHCARE, INC. (VMD) Stock Analysis — April 2026 Rating, Price, and Forecast
Company Overview — What Does VIEMED HEALTHCARE, INC. Do?
Viemed Healthcare, Inc., through its subsidiaries, provides in-home durable medical equipment (DME) and post-acute respiratory healthcare services to patients in the United States. It provides respiratory disease management solutions, including treatment of chronic obstructive pulmonary disease (COPD), which include non-invasive ventilation, percussion vests, and other therapies; and invasive and non-invasive ventilation and related equipment and supplies to patients suffering from COPD. The company also leases non-invasive and invasive ventilators, positive airway pressure machines (PAP), percussion vests, oxygen concentrator units, and other small respiratory equipment; and sells and rents DME and patient medical services. In addition, it provides neuromuscular care and oxygen therapy services; and sleep apnea management related solutions and/or equipment, such as PAP, automatic continuous positive airway pressure, and bi-level positive airway pressure machines. Further, the company offers in home sleep apnea testing services. Viemed Healthcare, Inc. was founded in 2006 and is headquartered in Lafayette, Louisiana. VIEMED HEALTHCARE, INC. (VMD) is classified as a small-cap stock in the Healthcare sector. The company is led by CEO Casey Hoyt and employs approximately 630 people. With a market capitalization of $370M, VMD is one of the notable companies in the Healthcare sector.
VIEMED HEALTHCARE, INC. (VMD) Stock Rating — Hold (April 2026)
As of April 2026, VIEMED HEALTHCARE, INC. receives a Hold rating with a composite score of 53.4/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.VMD ranks #167 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, VIEMED HEALTHCARE, INC. ranks #3 of 838 stocks, placing it in the top 10% of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).
VMD Stock Price and 52-Week Range
VIEMED HEALTHCARE, INC. (VMD) currently trades at $9.51. The stock gained $0.02 (0.2%) in the most recent trading session. The 52-week high for VMD is $10.06, which means the stock is currently trading -5.5% from its annual peak. The 52-week low is $5.93, putting the stock 60.4% above its annual trough. Recent trading volume was 209K shares, suggesting relatively thin trading activity.
Is VMD Overvalued or Undervalued? — Valuation Analysis
VIEMED HEALTHCARE, INC. (VMD) carries a value factor score of 63/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The trailing price-to-earnings ratio is 28.10x, compared to the Healthcare sector average of 23.63x — a premium of 19%. The price-to-book ratio stands at 2.64x, versus the sector average of 2.75x. The price-to-sales ratio is 1.50x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, VMD trades at 17.47x EV/EBITDA, versus 6.34x for the sector.
Overall, VMD's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.
VIEMED HEALTHCARE, INC. Profitability — ROE, Margins, and Quality Score
VIEMED HEALTHCARE, INC. (VMD) earns a quality factor score of 50/100, indicating solid business quality with consistent operational execution. The return on equity (ROE) is 9.4%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at 6.8% versus the sector average of -33.1%.
On a margin basis, VIEMED HEALTHCARE, INC. reports gross margins of 57.8%, compared to 71.5% for the sector. The operating margin is 8.0% (sector: -66.1%). Net profit margin stands at 5.4%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 30.8% on a trailing basis, compared to 10.6% for the sector. The overall profitability profile is adequate, though there may be room for margin expansion.
VMD Debt, Balance Sheet, and Financial Health
VIEMED HEALTHCARE, INC. has a debt-to-equity ratio of 39.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 1.18x, suggesting adequate working capital coverage. Cash and equivalents stand at $11M.
VMD has a beta of 0.77, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for VIEMED HEALTHCARE, INC. is 69/100, reflecting average volatility within the normal range for its sector.
VIEMED HEALTHCARE, INC. Revenue and Earnings History — Quarterly Trend
In TTM 2026, VIEMED HEALTHCARE, INC. reported revenue of $252M and earnings per share (EPS) of $0.38. Net income for the quarter was $13M. Gross margin was 57.8%. Operating income came in at $20M.
In FY 2025, VIEMED HEALTHCARE, INC. reported revenue of $270M and earnings per share (EPS) of $0.38. Net income for the quarter was $15M. Gross margin was 57.5%. Revenue grew 20.5% year-over-year compared to FY 2024. Operating income came in at $23M.
In Q3 2025, VIEMED HEALTHCARE, INC. reported revenue of $72M and earnings per share (EPS) of $0.09. Net income for the quarter was $4M. Gross margin was 57.5%. Revenue grew 24.0% year-over-year compared to Q3 2024. Operating income came in at $6M.
In Q2 2025, VIEMED HEALTHCARE, INC. reported revenue of $63M and earnings per share (EPS) of $0.08. Net income for the quarter was $3M. Gross margin was 58.3%. Revenue grew 14.7% year-over-year compared to Q2 2024. Operating income came in at $5M.
Over the past 8 quarters, VIEMED HEALTHCARE, INC. has demonstrated a growth trajectory, with revenue expanding from $55M to $252M. Investors analyzing VMD stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.
VMD Dividend Yield and Income Analysis
VIEMED HEALTHCARE, INC. (VMD) does not currently pay a dividend. This is common among smaller companies in the Healthcare industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.
VMD Momentum and Technical Analysis Profile
VIEMED HEALTHCARE, INC. (VMD) has a momentum factor score of 60/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 24/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 47/100 reflects moderate short selling activity.
VMD vs Competitors — Healthcare Sector Ranking and Peer Comparison
Comparing VMD against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full VMD vs S&P 500 (SPY) comparison to assess how VIEMED HEALTHCARE, INC. stacks up against the broader market across all factor dimensions.
VMD Next Earnings Date
No upcoming earnings date has been announced for VIEMED HEALTHCARE, INC. (VMD) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.
Should You Buy VMD? — Investment Thesis Summary
VIEMED HEALTHCARE, INC. presents a balanced picture with arguments on both sides. The value score of 63/100 suggests attractive pricing relative to fundamentals. Price momentum is positive at 60/100, suggesting the trend favors buyers. Low volatility (stability score 69/100) reduces downside risk.
In summary, VIEMED HEALTHCARE, INC. (VMD) earns a Hold rating with a composite score of 53.4/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on VMD stock.
We'll email you when stocks you follow change their composite rating.
Institutional Research Dossier
VIEMED HEALTHCARE, INC. (VMD) Deep Dive Analysis
Published on March 24, 2026
Action RatingHold
Sections
Executive Summary
Viemed Healthcare, Inc. currently holds a 'Hold' rating, reflecting a balanced assessment of its growth prospects and inherent risks. While the company demonstrates strong revenue growth and attractive valuation multiples compared to the healthcare sector, concerns regarding its relatively lower gross margins and the sustainability of its growth trajectory warrant caution. Investors should closely monitor the company's ability to maintain its competitive edge and navigate the evolving regulatory landscape within the durable medical equipment (DME) and respiratory healthcare services industry.
The company's focus on in-home respiratory care presents a compelling opportunity given the aging population and increasing prevalence of chronic respiratory diseases. However, the 'Hold' rating acknowledges the need for further evidence of consistent profitability and efficient capital allocation before a more bullish stance can be justified. The relatively low Investment score in the BCR proprietary quant model underscores the importance of scrutinizing Viemed's capital deployment strategies and their impact on long-term shareholder value.
Business Strategy & Overview
Viemed Healthcare operates within the durable medical equipment (DME) and respiratory healthcare services sector, focusing on providing in-home solutions for patients with chronic respiratory conditions such as COPD. The company's core business revolves around leasing and selling respiratory equipment, including ventilators, oxygen concentrators, and PAP machines, along with providing related services like respiratory disease management and sleep apnea testing. This strategy capitalizes on the growing demand for home-based healthcare, driven by factors such as an aging population, increasing prevalence of chronic diseases, and a preference for cost-effective and convenient care settings.
The company differentiates itself by offering a comprehensive suite of respiratory care solutions, encompassing both equipment and services, which allows it to establish long-term relationships with patients and healthcare providers. Viemed's strategy also involves expanding its geographic footprint and service offerings through organic growth and strategic acquisitions. This approach enables the company to reach a wider patient base and diversify its revenue streams. The company's focus on respiratory care positions it within a niche market that benefits from relatively stable demand and favorable reimbursement policies.
Viemed's business model relies heavily on reimbursement from government and private payers. The company's ability to secure favorable reimbursement rates and navigate the complex regulatory landscape is crucial to its financial performance. Changes in reimbursement policies or increased regulatory scrutiny could significantly impact the company's revenue and profitability. The company's growth strategy also depends on its ability to effectively manage its operations and maintain high-quality service standards as it expands its geographic reach and service offerings.
The company's strategic positioning within the in-home respiratory care market offers both opportunities and challenges. While the demand for home-based healthcare is expected to continue to grow, Viemed faces competition from other DME providers, respiratory care companies, and traditional healthcare settings. The company's ability to differentiate itself through superior service, innovative solutions, and strong relationships with healthcare providers will be critical to its long-term success. Furthermore, the company must continue to invest in technology and infrastructure to support its growth and maintain its competitive edge.
Execution Benchmarks audit
Revenue Growth
YOY expansion rate
30.8%
Sector: 10.6%
+190% VS SCTR
Economic Moat Analysis
Viemed's economic moat can be classified as Narrow. While the company operates in a specialized niche within the healthcare sector, its competitive advantages are not strong enough to warrant a Wide moat rating. The primary sources of its moat stem from switching costs and intangible assets, although these are not insurmountable for competitors.
Switching costs arise from the established relationships Viemed cultivates with patients and healthcare providers. Patients who are comfortable with Viemed's equipment and services may be hesitant to switch to a new provider, especially given the critical nature of respiratory care. Similarly, healthcare providers may prefer to work with a trusted partner who can provide reliable equipment and support. However, these switching costs are not prohibitive, as patients can switch providers if they are dissatisfied with Viemed's service or if a competitor offers a significantly better value proposition.
Intangible assets, such as brand reputation and proprietary knowledge, also contribute to Viemed's moat. The company has built a reputation for providing high-quality respiratory care services, which can attract new patients and healthcare providers. Additionally, Viemed may possess proprietary knowledge related to respiratory disease management and patient care, which gives it a competitive edge. However, these intangible assets are not unique to Viemed, as other companies in the industry also have strong reputations and specialized expertise.
The company does not appear to possess significant cost advantages or benefit from efficient scale. The DME industry is relatively fragmented, and there are numerous providers of respiratory equipment and services. Viemed's gross margins are lower than the sector average, suggesting that it does not have a significant cost advantage over its competitors. Additionally, the company's size and market share are not large enough to create significant economies of scale.
Network effects are not a significant factor in Viemed's business model. While the company benefits from relationships with healthcare providers, these relationships do not create a strong network effect that would make it difficult for competitors to enter the market. Overall, Viemed's narrow moat provides it with some competitive advantages, but it is not immune to competition from other players in the industry. The company must continue to innovate and differentiate itself to maintain its market position.
Financial Health & Profitability
Viemed's financial health presents a mixed picture. The company has demonstrated strong revenue growth, with a TTM revenue of $270.28 million, representing a 30.8% increase compared to the sector average of 10.7%. This growth is further evidenced by the consistent sequential revenue increases observed in the quarterly financial history. However, the company's gross margin of 57.8% is significantly lower than the sector average of 71.9%, indicating potential inefficiencies in its cost structure or pricing strategy.
The company's profitability metrics, such as net income and operating margin, are positive and compare favorably to the sector averages, which are negative. Viemed's net income of $15.38 million and operating margin of 8.0% demonstrate its ability to generate profits from its operations. The company's ROE of 9.4% is also significantly higher than the sector average of -42.5%, indicating efficient use of equity to generate profits.
Viemed's balance sheet appears to be relatively healthy. The company has $11.12 million in total cash and a current ratio of 1.18, suggesting sufficient liquidity to meet its short-term obligations. The company's debt-to-equity ratio of 39.00 is slightly higher than the sector average of 30.00, but it does not appear to be excessively leveraged. The absence of free cash flow data makes it difficult to assess the company's cash flow generation capabilities.
Analyzing the quarterly financial history reveals a consistent trend of revenue growth and profitability. However, the gross margin has fluctuated slightly over time, indicating potential variability in the company's cost structure or pricing strategy. The operating margin has also shown some variability, suggesting that the company's operating expenses are not always perfectly aligned with its revenue growth. Overall, Viemed's financial health is relatively sound, but the company needs to improve its gross margin and maintain its profitability as it continues to grow.
Valuation Assessment
Viemed's valuation presents a compelling case for value investors, particularly when compared to its healthcare sector peers. The company's P/E ratio of 22.9x is slightly below the sector average of 24.3x, suggesting that the stock is fairly valued relative to its earnings. However, the EV/EBITDA multiple of 3.4x is significantly lower than the sector average of 6.4x, indicating that the company may be undervalued based on its enterprise value and earnings before interest, taxes, depreciation, and amortization.
Given the company's strong revenue growth of 30.8%, which significantly exceeds the sector average of 10.7%, a higher valuation multiple might be warranted. The combination of above-average growth and below-average valuation multiples suggests that the stock may be undervalued by the market. However, it is important to consider the company's relatively lower gross margin and the potential risks associated with its business model before concluding that the stock is a bargain.
The absence of free cash flow data makes it difficult to assess the company's valuation based on its cash flow generation capabilities. Free cash flow is a key metric for valuing companies, as it represents the cash flow available to investors after all operating expenses and capital expenditures have been paid. Without this data, it is difficult to determine whether the company is generating sufficient cash flow to support its growth and return capital to shareholders.
Overall, Viemed's valuation appears to be attractive based on its P/E and EV/EBITDA multiples, particularly when considering its strong revenue growth. However, the relatively lower gross margin and the absence of free cash flow data warrant caution. Investors should conduct further due diligence to assess the company's long-term growth prospects and its ability to generate sustainable cash flow before making an investment decision. The BCR proprietary quant model's Value score of 65/100 supports the notion that the stock is relatively undervalued.
Risk & Uncertainty
Viemed faces several specific risks that could negatively impact its business and financial performance. One of the most significant risks is regulatory uncertainty. The DME industry is subject to complex and evolving regulations, particularly regarding reimbursement policies and healthcare fraud. Changes in these regulations could significantly impact Viemed's revenue and profitability. For example, reductions in reimbursement rates for respiratory equipment or services could reduce the company's revenue, while increased regulatory scrutiny could lead to higher compliance costs.
Another key risk is competition. The DME industry is relatively fragmented, and Viemed faces competition from other DME providers, respiratory care companies, and traditional healthcare settings. Increased competition could lead to price wars, reduced market share, and lower profitability. Viemed's ability to differentiate itself through superior service, innovative solutions, and strong relationships with healthcare providers will be critical to mitigating this risk.
Concentration risk is also a concern. Viemed's revenue may be concentrated among a small number of key customers or geographic regions. The loss of a major customer or a significant disruption in a key geographic region could significantly impact the company's revenue and profitability. Viemed needs to diversify its customer base and geographic footprint to reduce this risk.
The company's growth strategy also presents risks. Viemed's growth depends on its ability to effectively manage its operations and maintain high-quality service standards as it expands its geographic reach and service offerings. Failure to effectively manage its growth could lead to operational inefficiencies, reduced service quality, and damage to its reputation.
Bulls Say / Bears Say
The Bull Case
BULL VIEWViemed's strong revenue growth in the expanding home healthcare market, coupled with its attractive valuation multiples, positions it for significant upside potential.
BULL VIEWThe company's focus on respiratory care, a niche market with stable demand and favorable reimbursement policies, provides a solid foundation for long-term growth and profitability.
BULL VIEWViemed's positive net income and operating margin, in contrast to negative sector averages, demonstrate its superior operational efficiency and ability to generate profits.
The Bear Case
BEAR VIEWViemed's relatively low gross margin compared to the sector average raises concerns about its cost structure and pricing power, potentially limiting its long-term profitability.
BEAR VIEWThe absence of free cash flow data makes it difficult to assess the company's cash flow generation capabilities and its ability to fund future growth and return capital to shareholders.
BEAR VIEWRegulatory uncertainty and increasing competition in the DME industry pose significant risks to Viemed's business model and could negatively impact its revenue and profitability.
About the Author
Marques Blank
Founder & Chief Investment Officer, Blank Capital
Marques brings 15 years of institutional finance and investing experience, having overseen financial planning for a $1.6B defense business unit. He developed the proprietary 6-factor quantitative model used to score VMD and 4,400+ other equities.
VIEMED HEALTHCARE, INC. exhibits a 45% valuation premium relative to institutional benchmarks. This represents a potential valuation overextension based on current multiples.
Return on Assets
Efficiency of asset utilization
6.8%
Sector: -33.1%
Gross Margin
Pricing power and cost efficiency
57.8%
Sector: 71.5%
Operating Margin
Core business profitability
8.0%
Sector: -66.1%
Net Margin
Bottom-line profitability
5.4%
Sector: -58.7%
Factor Methodology
The Quality factor evaluates the persistence and magnitude of cash flows. Companies with scores >70 exhibit superior competitive moats and financial resilience through economic cycles.
